-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer (PCa) is one of the most common malignant urinary system tumors in men
PCa mainly occurs in the peripheral area of the prostate, only about 30% occurs in the TZ PCa mainly occurs in the peripheral area of the prostate, and only about 30% occurs in the TZ
Recently, researchers from China published an article in the "Prostate" magazine, aiming to compare 18F-DCFPyL positron emission tomography (PET) and multi-parameter magnetic resonance imaging (mp-MRI) in diagnosing transitional zone (TZ) prostate cancer (PCa) performance
To compare the performance of 18F-DCFPyL positron emission tomography (PET) and multi-parameter magnetic resonance imaging (mp-MRI) in the diagnosis of transition zone (TZ) prostate cancer (PCa).
The study was designed retrospectively and included 20 patients receiving 18 F-DCFPyL PET/MRI and 32 patients receiving 18 F-DCFPyL PET/CT and MRI from January 2019 to June 2020
It was found that out of 52 patients, 43 had TZ PCa
18 Diagnostic performance of F-DCFPyL PET and MRI in TZ PCa
18 Diagnostic performance of F-DCFPyL PET and MRI in TZ PCaIn summary, these results show that the interpretation results of 18 F-DCFPyL PET have almost nothing to do with the doctor’s experience.
The interpretation result of 18 F-DCFPyL PET has almost nothing to do with the doctor’s experience.
Original source:
Yachao Liu, Yanliang Dong, Jiajin Liu et al.
Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer
in this message